Press releases
-
-
Internal link Lilly and ProQR to Expand RNA Editing Collaboration
-
-
-
Internal link ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference
-
Internal link ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
-
-
-
Internal link ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
-
-
-
-
-
Internal link ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
-
-
-
-
-
Internal link ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
-
Internal link ProQR to Present at Upcoming SVB Leerink Conference
-
Internal link ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
-
-
Internal link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
-
-
Internal link ProQR Announces Results for the Third Quarter of 2017